Literature DB >> 2894945

In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.

S V Otton1, R U Brinn, L F Gram.   

Abstract

Competitive inhibition studies using human liver microsomes have shown that quinidine (QD) has an exceptionally high affinity (60 nM) for the genetically variable cytochrome P-450 that catalyzes the formation of 4-hydroxydebrisoquine and dehydrosparteines from debrisoquine and sparteine. The present study examined the effect of sparteine and debrisoquine on the oxidation of QD by microsomes prepared from two human livers. QD and its major metabolite 3-hydroxy-QD were measured by quantitative TLC. QD 3-hydroxylation followed saturable single-site kinetics over a 1-250 microM range of QD concentrations. The Km and Vmax of the reaction in the two liver specimens were 47.5 +/- 3.5 microM and 58.7 +/- 5.9 microM, and 0.36 +/- 0.08 and 0.29 +/- 0.02 nmol of 3-hydroxy-QD/mg of protein/min. Sparteine and debrisoquine (250 microM) had no effect on this QD 3-hydroxylase activity. Furthermore, near-saturation of the sparteine/debrisoquine isozyme by 250 microM sparteine had no effect on the oxidation of QD by all routes (measured by QD disappearance from an initial level of 70 nM during an 8-hr incubation period). These observations indicate that none of the major oxidative reactions of QD are catalyzed by the sparteine/debrisoquine isozyme; QD may simply bind to this cytochrome P-450, without being oxidized by it.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894945

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

2.  Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:  L F Gram; D Debruyne; V Caillard; J P Boulenger; J Lacotte; M Moulin; E Zarifian
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

3.  Metabolic disposition of ajmaline.

Authors:  C Köppel; J Tenczer; I Arndt
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

4.  Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.

Authors:  Natalícia de Jesus Antunes; Ricardo Carvalho Cavalli; Maria Paula Marques; Elaine Christine Dantas Moisés; Vera Lucia Lanchote
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

5.  Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.

Authors:  D J Foster; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

6.  Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.

Authors:  Ryan P Seguin; Josi M Herron; Vanessa A Lopez; Joseph L Dempsey; Libin Xu
Journal:  Chem Res Toxicol       Date:  2019-12-03       Impact factor: 3.739

7.  Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Authors:  P Dalén; M Dahl; K Andersson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 8.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

9.  Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.

Authors:  F Nielsen; J U Rosholm; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

Authors:  K Brøsen; F Davidsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.